[Association of MiR-155 expression with prognosis in resected stage III non-small cell lung cancer]

Zhongguo Fei Ai Za Zhi. 2014 May;17(5):417-23. doi: 10.3779/j.issn.1009-3419.2014.05.10.
[Article in Chinese]

Abstract

Background and objective: Despite undergoing curative resection, the 5-year survival rate for stage III non-small cell lung cancer (NSCLC) patients is less than 25%. There is a need for biomarkers for prediction of survival and guiding individual therapy. MiR-155 is one of most commonly upregulated miRNAs in malignancies, and regulates multiple pro-oncogenic pathways. We aimed to investigate the prognostic impact of miR-155 in resected stage III NSCLC patients.

Methods: Tumor formalin-fixed, paraffin-embedded (FFPE) from 162 resected stage III NSCLC patients were collected. Total RNA including miRNA was extracted, and qRT-PCR was used to determine the expression of miR-155.

Results: Spearman rank correlation test showed a positive correlation between miR-155 expression and nodal status (r=0.169, P=0.032). MiR-155 expression had a significant prognostic impact in the total cohort (P<0.001), in squamous cell carcinomas (P=0.002) and in adenocarcinomas (P=0.003). In N0-1 subgroup, miR-155 expression did not have a significant prognostic on overall survival in univariate analysis (P=0.319). In N2 subgroup, miR-155 had a negative prognostic effect on OS in univariate analysis (P<0.001). Cox regression analysis revealed that miR-155 expression was unfavorable prognostic factors of OS (RR=2.311, 95%CI: 1.479-3.611, P<0.001).

Conclusions: High expression of miR-155 represents a valuable marker of poor clinical outcomes in patients with stage III NSCLC.

背景与目的 pIII期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者5年生存率低于25%,需要寻找新的预后标志物,指导患者个体化治疗。MiR-155在许多肿瘤中表达上调,并对肿瘤有广泛的调控作用。本研究旨在探讨手术切除的pIII期NSCLC中miR-155的表达与预后的关系。方法 采用qRT-PCR法检测162例pIII期NSCLC手术患者福尔马林固定石蜡包埋组织(formalin-fixed, paraffin-embedded, FFPE)中miR-155的表达。结果 miR-155在pIII期NSCLC中表达与淋巴结转移程度正相关(r=0.169, P=0.032)。单因素生存分析显示在总体队列(P<0.001)、鳞癌亚组(P=0.002)、腺癌亚组(P=0.003)中,miR-155高表达组的总体生存期(overall survival, OS)均低于miR-155低表达组。根据淋巴结转移程度分层分析显示在N0-1亚组中,miR-155高表达和低表达组间OS无统计学差异(P=0.319),在N2的患者中,miR-155高表达组OS显著低于miR-155低表达组(P<0.001)。多因素生存分析显示miR-155高表达是影响患者预后的独立危险因素(RR=2.311, 95%CI: 1.479-3.611, P<0.001)。结论 miR-15高表达不利于手术切除的pIII期NSCLC患者的总体生存,并且与淋巴结转移度正相关。MiR-155可作为评价pIII期NSCLC预后的生物标志物。

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / mortality
  • Male
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Survival Rate
  • Young Adult

Substances

  • MIRN155 microRNA, human
  • MicroRNAs

Grants and funding

本研究受湖北省卫生厅科研项目(No.JX6B06)资助